Cargando…

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

BACKGROUND: Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous iron preparations but clinical data on renal effects of intravenous iron are sparse. METHODS: FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with no...

Descripción completa

Detalles Bibliográficos
Autores principales: Macdougall, Iain C., Bock, Andreas H., Carrera, Fernando, Eckardt, Kai-Uwe, Gaillard, Carlo, Van Wyck, David, Meier, Yvonne, Larroque, Sylvain, Roger, Simon D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240256/
https://www.ncbi.nlm.nih.gov/pubmed/28095881
http://dx.doi.org/10.1186/s12882-017-0444-6
_version_ 1782496032155762688
author Macdougall, Iain C.
Bock, Andreas H.
Carrera, Fernando
Eckardt, Kai-Uwe
Gaillard, Carlo
Van Wyck, David
Meier, Yvonne
Larroque, Sylvain
Roger, Simon D.
author_facet Macdougall, Iain C.
Bock, Andreas H.
Carrera, Fernando
Eckardt, Kai-Uwe
Gaillard, Carlo
Van Wyck, David
Meier, Yvonne
Larroque, Sylvain
Roger, Simon D.
author_sort Macdougall, Iain C.
collection PubMed
description BACKGROUND: Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous iron preparations but clinical data on renal effects of intravenous iron are sparse. METHODS: FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with non-dialysis dependent chronic kidney disease (ND-CKD), anemia and iron deficiency without erythropoiesis-stimulating agent therapy received intravenous ferric carboxymaltose (FCM), targeting either higher (400–600 μg/L) or lower (100–200 μg/L) ferritin values, or oral iron. RESULTS: Mean (SD) eGFR at baseline was 34.9 (11.3), 32.8 (10.8) and 34.2 (12.3) mL/min/1.73 m(2) in the high ferritin FCM (n = 97), low ferritin FCM (n = 89) and oral iron (n = 167) groups, respectively. Corresponding values at month 12 were 35.6 (13.8), 32.1 (12.7) and 33.4 (14.5) mL/min/1.73 m(2). The pre-specified endpoint of mean (SE) change in eGFR from baseline to month 12 was +0.7 (0.9) mL/min/1.73 m(2) with high ferritin FCM (p = 0.15 versus oral iron), -0.9 (0.9) mL/min/1.73 m(2) with low ferritin FCM (p = 0.99 versus oral iron) and -0.9 (0.7) mL/min/1.73 m(2) with oral iron. No significant association was detected between quartiles of FCM dose, change in ferritin or change in TSAT versus change in eGFR. Dialysis initiation was similar between groups. Renal adverse events were rare, with no indication of between-group differences. CONCLUSION: Intravenous FCM at doses that maintained ferritin levels of 100–200 μg/L or 400–600 μg/L did not negatively impact renal function (eGFR) in patients with ND-CKD over 12 months versus oral iron, and eGFR remained stable. These findings show no evidence of renal toxicity following intravenous FCM over a 1-year period. TRIAL REGISTRATIONS: ClinicalTrials.gov NCT00994318 (first registration 12 October 2009). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0444-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5240256
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52402562017-01-19 Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial Macdougall, Iain C. Bock, Andreas H. Carrera, Fernando Eckardt, Kai-Uwe Gaillard, Carlo Van Wyck, David Meier, Yvonne Larroque, Sylvain Roger, Simon D. BMC Nephrol Research Article BACKGROUND: Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous iron preparations but clinical data on renal effects of intravenous iron are sparse. METHODS: FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with non-dialysis dependent chronic kidney disease (ND-CKD), anemia and iron deficiency without erythropoiesis-stimulating agent therapy received intravenous ferric carboxymaltose (FCM), targeting either higher (400–600 μg/L) or lower (100–200 μg/L) ferritin values, or oral iron. RESULTS: Mean (SD) eGFR at baseline was 34.9 (11.3), 32.8 (10.8) and 34.2 (12.3) mL/min/1.73 m(2) in the high ferritin FCM (n = 97), low ferritin FCM (n = 89) and oral iron (n = 167) groups, respectively. Corresponding values at month 12 were 35.6 (13.8), 32.1 (12.7) and 33.4 (14.5) mL/min/1.73 m(2). The pre-specified endpoint of mean (SE) change in eGFR from baseline to month 12 was +0.7 (0.9) mL/min/1.73 m(2) with high ferritin FCM (p = 0.15 versus oral iron), -0.9 (0.9) mL/min/1.73 m(2) with low ferritin FCM (p = 0.99 versus oral iron) and -0.9 (0.7) mL/min/1.73 m(2) with oral iron. No significant association was detected between quartiles of FCM dose, change in ferritin or change in TSAT versus change in eGFR. Dialysis initiation was similar between groups. Renal adverse events were rare, with no indication of between-group differences. CONCLUSION: Intravenous FCM at doses that maintained ferritin levels of 100–200 μg/L or 400–600 μg/L did not negatively impact renal function (eGFR) in patients with ND-CKD over 12 months versus oral iron, and eGFR remained stable. These findings show no evidence of renal toxicity following intravenous FCM over a 1-year period. TRIAL REGISTRATIONS: ClinicalTrials.gov NCT00994318 (first registration 12 October 2009). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0444-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-17 /pmc/articles/PMC5240256/ /pubmed/28095881 http://dx.doi.org/10.1186/s12882-017-0444-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Macdougall, Iain C.
Bock, Andreas H.
Carrera, Fernando
Eckardt, Kai-Uwe
Gaillard, Carlo
Van Wyck, David
Meier, Yvonne
Larroque, Sylvain
Roger, Simon D.
Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
title Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
title_full Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
title_fullStr Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
title_full_unstemmed Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
title_short Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
title_sort renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized find-ckd trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240256/
https://www.ncbi.nlm.nih.gov/pubmed/28095881
http://dx.doi.org/10.1186/s12882-017-0444-6
work_keys_str_mv AT macdougalliainc renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT bockandreash renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT carrerafernando renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT eckardtkaiuwe renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT gaillardcarlo renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT vanwyckdavid renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT meieryvonne renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT larroquesylvain renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT rogersimond renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial
AT renalfunctioninpatientswithnondialysischronickidneydiseasereceivingintravenousferriccarboxymaltoseananalysisoftherandomizedfindckdtrial